Comparison between levels of Homocysteine, Interleukin-6 and Interleukin-10 in severe cases of Egyptian COVID-19 patients

The Egyptian Journal of Immunology
Volume 30 (3), July, 2023
Pages: 110 – 123.
Wafaa A. Abdalwahed1, Eman F. Mohammed1, Walaa M. Shipl2, and Fatma M. Mabrouk1
1Department of Internal Medicine, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt.

2Department of Biochemistry, Faculty of Medicine (Girls), Al-Azhar University, Al-Azhar University, Cairo, Egypt.

Corresponding author:
Wafaa A. Abdalwahed, Department of Internal Medicine, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt.



Coronavirus disease 2019 (COVID-19) is the reason of an outbreak of respiratory illnesses ranging from typical cold to severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome. We intended to compare levels of IL-6, IL-10, and homocysteine in the sera of severe COVID-19 Egyptian patients and connect them with the extent of the illness. This cross-sectional study included 90 COVID-19 Egyptian patients. They included 45 non severe cases (group 1) and 45 severe cases (group 2). There was statistically significantly increase in IL-6 in group 2 (median = 7.05, IQR = 6.2 – 7.9; p<0.001) in comparison to group 1 (median = 4.96, IQR = 4.5 – 5.8) and statistically significantly increase in IL-10 in group 2 (154.1 ± 73.3) in comparison to group 1 (47.04 ± 23.8; p<0.001). There were no variations in the examined groups’ homocysteine levels (p= 0.318). Furthermore, there was statistically substantial positive connection (r=0.30) between IL-6 and AST (p=0.046) and between IL-10 and HCT (r = 0.37, p=0.012). In addition, data of other studied parameters are presented. In conclusion, IL-6 and IL-10 could be proposed for follow up of COVID-19 patients and to detect cases before progressing to a severe disease stage.

COVID-19, IL-6, IL-10, and homocysteine.

Date received:
05 January 2023; accepted: 05 June 2023



Full Text